1. Home
  2. Existing

Tags : Existing

Merck KGaA Takes an Early Option in its Existing Immuno-Oncology Collaboration with F-star

Merck KGaA Takes an Early Option in its Existing Immuno-Oncology

Tuba Khan July 17, 2020

Shots: F-star to receive option exercise payment and will be eligible to get milestones and royalties on net sales of therapies resulting from the collaboration. Merck KGaA exercises its option to license a preclinical program in its existing agreement with F-star Merck KGaA will be responsible for the development and commercialization of the preclinical program […]Read More

BMS Expands its Existing Patient Support Programs to Aid Uninsured Patients in the US Amid COVID-19

BMS Expands its Existing Patient Support Programs to Aid Uninsured

Tuba Khan April 8, 2020

Shots: The expanded program offers access to any branded BMS’s therapies for free, including its most widely prescribed therapies and those prescribed via telehealth services Patients can reach to BMS’ patient support programs by calling it on (800) 721-8909 or by visiting BMS.com. The program provides immediate access for patients who have lost their employment […]Read More

Vir and Alnylam Expand Their Existing Collaboration to Develop RNAi Therapeutics Targeting Host Factors for COVID-19

Vir and Alnylam Expand Their Existing Collaboration to Develop RNAi

Tuba Khan April 2, 2020

Shots: The collaboration will evaluate RNAi therapeutics targeting three host factors required for SARS-CoV-2 infection, including ACE2 and TMPRSS2. The third target is expected to emerge from Vir’s ongoing genomics efforts for identifying novel host factors relevant to COVID-19 Under the amended collaboration, Vir will be responsible for the development of selected DCs and the […]Read More

Galapagos Signs an Exclusive Option to License Agreement with Fibrocor to Expand their Existing 2019 Partnership for Fibrosis

Galapagos Signs an Exclusive Option to License Agreement with Fibrocor

Tuba Khan January 16, 2020

Shots: Fibrocor to receive upfront, option exercise fee, milestones and royalties on sales of the product. Galapagos to receive an exclusive option to in-license up to 4 targets, out of which two reached the lead optimization stage Galapagos takes an equity stake in Fibrocor and will get an exclusive global right to commercialize the developed […]Read More

Xiangxue Signs an Exclusive License Agreement with Athenex to Expand their Existing Partnership

Xiangxue Signs an Exclusive License Agreement with Athenex to Expand

Tuba Khan December 17, 2019

Shots: Athenex to receive $30M up front, ~$170M milestones and royalties on sales of licensed products in China, Hong Kong and Macao. Xiangxue to get exclusive license to develop & commercialize Athenex’s oral Paclitaxel, oral Irinotecan and Tirbanibulin ointment for the treatment of actinic keratosis (AK) in licensed territories The collaboration represents the expansion of […]Read More

Kyowa Kirin Signs Two Agreement with Ardelyx to Expand its Existing Partnership

Kyowa Kirin Signs Two Agreement with Ardelyx to Expand its

Tuba Khan November 26, 2019

Shots: As per the first agreement, Ardelyx to receive $10M for research and is eligible to receive ~10.5M upfront and up to $500M as development & commercialization milestone and will execute research in collaboration with Kyowa Kirin for only two targets Following the end of the research period, Kyowa Kirin to get an option to […]Read More

Celgene Amends its Existing Collaboration with Editas to Develop and Commercialize Autologous and Allogeneic T Cell Medicines for Cancer and Autoimmune Diseases

Celgene Amends its Existing Collaboration with Editas to Develop and

Tuba Khan November 13, 2019

Shots: Editas to receive $70M up front, milestone and royalty payments for each therapy developed by Celgene and will develop genome editing tool for which Celgene has right to opt-in to such genome editing tools for the development of gene-edited alpha-beta T cell therapies In May’2015, Editas and Juno entered into an exclusive collaboration to […]Read More

Copyright ©2020 PharmaShots | Powered by Octavus Consulting